Denosumab (anti-TNFSF11) 

Denosumab (anti-TNFSF11) is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (K_D of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies^{[1][2][3][4][5][6][7]}.

Human IgG2 kappa

Human IgG2 kappa, Isotype Control

Human

TNFSF11/RANKL/CD254

Denosumab (0.25-20 μM, 7 days) enhances osteogenic differentiation at physiological concentrations in human mesenchymal stem cells of the jaw bone^[4].
Denosumab (0.1 μM–5 μM) alleviates ROS-induced chondrocytes Apoptosis, with promoting Bcl-2 and suppressing pro-apoptotic genes Bax and caspase-3^[5].
Denosumab (5 μM, 5-60 min) suppresses RANKL-induced osteoclastogenesis by inhibiting the NF-κB signaling pathway^[5].
Denosumab (0.001-0.1 μg/mL, 24-72 h) significantly increases human β-cell proliferation^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Denosumab (10 mg/kg, s.c., twice a week for 4 weeks) ameliorates pain-related behaviors and osteoarthritis (OA) progression in the OA mouse model^[5].
Denosumab (1 mg/kg, s.c., single) enhances human β-cell proliferation in human islets transplanted under the kidney capsule of male euglycemic NOD/SCID mice^[6].
Denosumab (5 mg/kg, s.c., single) increases testis weight, inhibin B, and sperm count in humanized RANKL mice^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

8600  [NCBI]

O14788

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.16 kDa

615258-40-7

Liquid

Colorless to light yellow

[Denosumab (anti-TNFSF11)]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Flow Cytometry analysis of Hela cells labelling TNFSF11 (red) with Denosumab (anti-TNFSF11) (HY-P9958A). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG2 kappa (HY-P99002). Black-Unlabelled control, cells without incubation with primary antibody.

• [1]. 1. Moen MD, et al. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging. 2011;28(1):63-82.  [Content Brief]

  [2]. 2. Kendler DL, et al. Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review. Adv Ther. 2022 Jan;39(1):58-74.  [Content Brief]

  [3]. 3. Dell'Aquila E, et al. Denosumab for cancer-related bone loss. Expert Opin Biol Ther. 2020 Nov;20(11):1261-1274.  [Content Brief]

  [4]. 4. Mosch A, et al. Physiological concentrations of denosumab enhance osteogenic differentiation in human mesenchymal stem cells of the jaw bone. Arch Oral Biol. 2019 May;101:23-29.  [Content Brief]

  [5]. 5. Shangguan L, et al. Denosumab ameliorates osteoarthritis by protecting cartilage against degradation and modulating subchondral bone remodeling. Regen Ther. 2024 Mar 26;27:181-190.  [Content Brief]

  [6]. 6. Kondegowda NG, et al. Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-κB Ligand Pathway. Cell Metab. 2015 Jul 7;22(1):77-85.  [Content Brief]

  [7]. 7. Andreassen CH, et al. Denosumab stimulates spermatogenesis in infertile men with preserved Sertoli cell capacity. Cell Rep Med. 2024 Oct 15;5(10):101783.  [Content Brief]